Oct 25, 2007 - "Prochymal has shown promise in Phase II clinical trials as a therapy for severe immune mediated conditions including Crohn's Disease and GVHD, and as a result has advanced into Phase III pivotal trials," said C. Randal Mills, Ph.D., President and CEO of Osiris Therapeutics. "It is appropriate to evaluate related conditions such as type 1 diabetes, where data indicates Prochymal may also be of therapeutic benefit. We are honored that JDRF has selected Prochymal as a promising new therapy for evaluation."... Osiris Therapeutics' Press Release -
Monday, November 19, 2007
Osiris Therapeutics, Phase II Clinical Trial Evaluating Prochymal(TM) for Type 1 Diabetes
Oct 25, 2007 - "Prochymal has shown promise in Phase II clinical trials as a therapy for severe immune mediated conditions including Crohn's Disease and GVHD, and as a result has advanced into Phase III pivotal trials," said C. Randal Mills, Ph.D., President and CEO of Osiris Therapeutics. "It is appropriate to evaluate related conditions such as type 1 diabetes, where data indicates Prochymal may also be of therapeutic benefit. We are honored that JDRF has selected Prochymal as a promising new therapy for evaluation."... Osiris Therapeutics' Press Release -
